T he increased mortality associated with the use of the class Ic agents encainide and flecainide in the Cardiac Arrhythmia Suppression Trial (CAST)' has led to a critical reexamination of the adequacy of existing therapies for the control of cardiac arrhythmias. Although the reasons for the findings in CAST remain unclear, proarrhythmia due to excessive slowing of conduction has been suggested as a possible contributing cause. prolongation at slow heart rates, which might lead to proarrhythmia. This pattern of activity, that is, reduced efficacy at fast heart rates and increased efficacy at slow heart rates, is opposite to that typically observed with class I agents,9 which tend to exhibit greater pharmacological effects (i.e., more conduction slowing) as heart rate is increased. The decline in class III activity at fast heart rates has been attributed to a phenomenon called "reverse" usedependence,8 by which potassium channel block is relieved by depolarization and enhanced by hyperpolarization, the reverse of what occurs with the sodium channel blockers. This particular paradigm for potassium channel block is based on an analysis of the effects of the class Ia agent quinidine on delayed rectifier potassium currents in guinea pig ventricular myocytes.10
T he increased mortality associated with the use of the class Ic agents encainide and flecainide in the Cardiac Arrhythmia Suppression Trial (CAST)' has led to a critical reexamination of the adequacy of existing therapies for the control of cardiac arrhythmias. Although the reasons for the findings in CAST remain unclear, proarrhythmia due to excessive slowing of conduction has been suggested as a possible contributing cause.2 Consequently, drugs that act by mechanisms other than sodium channel block, for example, /8-blockers and the class III antifibrillatory agents, are currently receiving renewed interest as possible alternative therapies. Although the beneficial effect of ,8-blockade in postinfarction patients has been clearly established in several randomized trials,3 much less is known about the efficacy and overall safety of the class III antiarrhythmic agents. Preliminary results, however, suggest that the class III agents generally demonstrate greater efficacy than conventional class I agents in preventing ventricular arrhythmias occurring during acute ischemia or evoked by programmed electrical stimulation, while producing less cardiac depression than other antiarrhythmic drug classes. [4] [5] [6] Available data suggest that most class III agents exert their effects on repolarization by blocking one or more potassium channels.7 In a recent "Point of View," Hondeghem and Snyders8 suggest that the therapeutic potential of currently available class III antiarrhythmics is limited by 1) a diminished ability to prolong repolarization at fast heart rates, which would reduce their effectiveness in terminating tachycardias, and 2) a tendency to produce excessive
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prolongation at slow heart rates, which might lead to proarrhythmia. This pattern of activity, that is, reduced efficacy at fast heart rates and increased efficacy at slow heart rates, is opposite to that typically observed with class I agents,9 which tend to exhibit greater pharmacological effects (i.e., more conduction slowing) as heart rate is increased. The decline in class III activity at fast heart rates has been attributed to a phenomenon called "reverse" usedependence,8 by which potassium channel block is relieved by depolarization and enhanced by hyperpolarization, the reverse of what occurs with the sodium channel blockers. This particular paradigm for potassium channel block is based on an analysis of the effects of the class Ia agent quinidine on delayed rectifier potassium currents in guinea pig ventricular myocytes.10
In the present article, we review briefly the role of myocardial potassium channels as targets for class I and class III antiarrhythmic drug action, and suggest a model for the drug-channel interaction that is most consistent with the information currently available on potassium channel block in several different cardiac preparations. Our investigations indicate that potassium channel block by both class I and class III antiarrhythmic agents is enhanced by depolarization and removed by hyperpolarization, and is therefore identical to the type of use-dependence described previously for drug block of sodium channels. This model is supported by direct measurements of delayed rectifier currents in cat ventricular myocytes that are consistent with drug block and unblock of open channels. Finally, we demonstrate that agents that prolong refractoriness by delaying the recovery of sodium channels carry some intrinsic potential for arrhythmia aggravation because they can introduce nonuniformities in otherwise homogeneous tissue by prolonging the diastolic "window" '4 Similarly, drugs that selectively block the transient outward current, 'to, may be expected to produce more dramatic increases in action potential duration (APD) at slow heart rates because the slow reactivation kinetics of this current minimize its contribution to the action potential at short cycle lengths.15 To date, no such agent has been identified ( Table 1) . Several studies, however, suggest that 'to is extremely prominent in atrial myocytes and may be the primary repolarizing current in this region of the heart. Consequently, selective inhibition of Ito may, in theory, offer some specificity for the suppression of supraventricular arrhythmias. Most clinical experience to date has been with class III agents that inhibit the delayed rectifier current. This approach is attractive for several reasons. First, the contribution of Ik to repolarization should be greater at shorter cycle lengths because the slow deactivation of Ik during diastole will result in a progressive accumulation of open (residually activated) channels from one action potential to the next.16 Second, the effect of agents acting by this mechanism should be amplified in depolarized tissue because the inwardly rectifying properties of the channel will accentuate drug effects at potentials between -60 and -40, at which the fully activated current-voltage relation provides maximal outward current. These considerations support selective block of Ik as a reasonable first approach in the design of new class III antiarrhythmic agents.
Excessive prolongation of repolarization may sometimes be associated with the onset of a polymorphic ventricular tachycardia that can be diagnosed as torsade de pointes.'7 This particular arrhythmia is most commonly induced by the class Ia antiarrhythmics but is relatively rare during therapy with class Ib Colatsky et al Antiarrhythmic Drug Specificity 2237 and Ic agents. Because experience is more limited, the picture for the class III agents is less clear at this time. Sotalol has been reported to induce torsade de pointes at high concentrations, as well as at lower concentrations, in the presence of hypokalemia or with coadministration of other agents that prolong repolarization. 17 The incidence of torsade de pointes with amiodarone appears to be lower than expected, however, based on its ability to dramatically increase the QT interval. 18 It is intriguing to speculate that drugs that block multiple channel types exhibit a greater tendency to produce proarrhythmia than drugs that specifically inhibit one channel only. The class Ia agents, which block lk, lkl, and 'to nonselectively, have a high incidence of torsade de pointes. The class Ic agents, encainide and flecainide, inhibit Ik only but produce an incessant polymorphic ventricular tachycardia that is distinct from torsade de pointes in that it is associated with fast heart rates and excessive conduction slowing rather than pauses and QT prolongation. Figure 1 (panel  A) . In the absence of drug, depolarizations to 50 mV completely activate lk, which then decays on repolarization to -65 mV with a time constant of 208 msec. Encainide reduces the peak amplitude of the Ik tail current to 32% of its control value and slows the deactivation time constant to 322 msec, resulting in a crossover of the control and treatment traces at later times. Additionally, tail currents in the presence of encainide show a distinct rising phase immediately after the repolarization step. Similar behavior has been reported for the quaternary ammonium compounds in nerve,21,22 and can be explained if the drug prevents channel closure on repolarization and unbinds at negative potentials. The lower panel ( Figure  1, panel B) shows the result of a simulation in which this model was tested quantitatively. The predicted current waveform is reasonably close to that obtained experimentally and supports drug interactions with channels in the open state. Additionally, the model predicts that drug unbinding is fast, or at least as fast as the time course of Ik deactivation.
A different picture, however, emerges from studies in guinea pig ventricular cells, in that hyperpolarization appears to increase the level of block, whereas depolarization reduces it.10 In these experiments, quinidine significantly delayed activation of lk, as measured by tail current amplitude, without altering the later time course of activation. These results, however, could also be explained if quinidine selectively blocked a small and more rapidly activating component of tail current that is normally buried within the larger Ik.10,23 "Big lk" and "Little k" Recent voltage clamp studies in ventricular myocytes by several investigators have begun to clarify the number and types of delayed rectifier potassium channels present in the myocardial cell membrane. Although some differences exist, the delayed rectifier currents now being described in isolated myocytes are generally similar to those reported by Noble similar conditions.4-6 Moreover, there is a growing body of clinical data supporting a greater efficacy of the class III agents against sustained ventricular tachycardia when evaluated in comparator trials against class I agents such as procainamide. 43, 44 These data indicate that the blunted ability of the class III agents to prolong APD at fast heart rates does not greatly diminish their antiarrhythmic efficacy compared with class I agents. One possible explanation is that very rapid heart rates may be less likely to develop when APD is prolonged because the increase in refractoriness will prevent premature beats from triggering reentry, as well as reduce the probability that randomly occurring reentrant circuits will be sustained. It is also possible that decreases in membrane potential will enhance the effects of blockers of Ik on APD because 1) Ik will decay more slowly during diastole in abnormally depolarized cells, allowing it to play a greater role in providing residual outward current for repolarization, and 2) drug will unbind from channels more slowly at less negative potentials because of the intrinsic voltage dependence of the drug-channel interaction.20 Also, as mentioned previously, depolarization will enhance the contribution of Ik to repolarization because the inwardly rectifying properties of the channel provide maximal outward current over this potential range. Finally, it should be realized that although class III effects are diminished at short cycle lengths, they are nevertheless still present. For example, Steinberg et a145 report increases in APD of 28% versus 14% for clofilium at cycle lengths of 1,400 and 370 msec, respectively, whereas in other studies, d-sotalol increased ventricular effective refractory period in patients by 18% at a cycle length of 500 msec. 46 Similarly, Hayward and Taggart47 found that the class III effects of sotalol on atrial APD and refractoriness in humans were retained both during overdrive pacing and with premature stimulation. Nevertheless, there is still an apparent paradox in that although frequent depolarizations should enhance class III activity, this is generally not seen in practice. The most likely explanation is that there is not necessarily a direct proportionality between lk block and action-potential prolongation because the contribution of other channels to repolarization (e.g., calcium channel inactivation) may become increasingly important at short cycle lengths. Further studies using more selective blockers of the different K' channels may help to resolve this issue.
Proarrhythmicity Window for Class I Agents It is well appreciated that the class I agents block the excitatory sodium channel and reduce cardiac excitability and conduction in a time-and voltagedependent manner, and that changes in refractoriness can be obtained by delaying the recovery of the sodium channel from inactivation.9 There is necessarily a period of time between full excitability (normal conduction) and full inexcitability (refractoriness), however, during which the cell is only partially excitable and premature stimulation leads to slow conduction and a wide variety of cellular activation patterns.
This situation has recently been simulated (Starmer, Lastra, and Grant, unpublished observations) by using the Beeler-Reuter cardiac action potential model in a long (4 cm) one-dimensional homogeneous cable, and a simple three-state binding scheme for the drug-channel interaction, in which channel block develops progressively as drug binds to a transiently available receptor.21,48 The cable was stimulated at one end at a cycle length of 1,000 msec, and conduction patterns and refractory periods mapped by probing the diastolic interval with a premature impulse applied to the midpoint of the cable every 10th beat. By using this procedure, an interval of time could be identified during which premature stimulation resulted in nonuniform conduction and unidirectional block (i.e., the vulnerable window). In the absence of a drug, the vulnerable window occurred near the tail of the action potential and was 5 msec in duration. When these calculations were repeated in the presence of a sodium channel blocker with fast recovery kinetics (time constant for drug unbinding, rff=250 msec), the vulnerable window was shifted to a point 41 msec after repolarization and its duration increased to 8 msec. Simulations of kinetically slower drugs (1-off = 667 msec and 1,250 msec) produced further increases in both refractoriness and vulnerable window that were well correlated with their blocking kinetics (Figure 2, panel A) .
These results suggest that sodium channel block can transform a homogeneous substrate into a heterogeneous one, with the attendant potential for the generation of new arrhythmia. Because unidirectional block has been postulated to be a prerequisite for the initiation of reentry, the probability that a randomly timed extrastimulus would produce unidirectional block was used as an index of proarrhythmic potential. This probability was calculated as the ratio 
